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The potency of the broad spectrum 
bacteriocin, bactofencin A, against 
staphylococci is highly dependent 
on primary structure, N-terminal 
charge and disulphide formation
Paula M. O’ Connor1,2, Eileen F. O’ Shea1,3, Paul D. Cotter  1,2, Colin Hill2,3 & R. Paul Ross2,3
Bactofencin A is a novel class IId bacteriocin, produced by the intestinal isolate Lactobacillus salivarius 
DPC6502, which has potent activity against medically significant pathogens including Staphylococcus 
aureus. This bacteriocin is unusual in that it has a highly cationic N terminus and a single disulfide 
bond between Cys7 and Cys22, resulting in a large C terminal loop. In this study, a library of synthetic 
bactofencin A variants were screened against the mastitis isolate, S. aureus DPC5246, to identify 
key residues responsible for activity. It was apparent that substituting either cysteine of the disulfide 
bond with either serine or alanine significantly reduced the activity of the bacteriocin, confirming the 
importance of the C terminal loop. Substituting N terminal amino acids with alanine had no effect 
on activity, whereas sequential removal of the N terminal positively charged residues resulted in 
an increasingly inactive peptide. A complete (synthetic) alanine scanning analysis revealed that the 
residues between Val9 and Gly17 were most affected by substitution suggesting that this area has a 
major influence on the potency of the bacteriocin. Substituting residues in the loop region between 
Cys7 and Cys22 for D-amino acid equivalents had a more detrimental effect on activity than L-alanine 
substitutions. Specifically Y10A, N11A, P15A and T16A are active at 4, 16, 1 and 16 μM respectively 
while their D equivalents were inactive at 1000 μM, the highest concentration tested. Ultimately, this 
study identifies the critical features in the primary structure of the bacteriocin which gives it such potent 
activity against pathogenic staphylococci.
Concerns about the increased incidence of antimicrobial resistance (AMR) against human pathogens have led 
to calls for global efforts to combat this worrying phenomenon. If left untackled once treatable infections will 
again become incurable1. The Global Antimicrobial Resistance Surveillance System (GLASS) was set up in 2015 
to standardise the collection and sharing of data on AMR at a global level and to promote coordinated action. In 
support of this initiative the WHO recently surveyed the development of new antibiotics in the clinical pipeline 
against priority pathogens and found that there is particular need for new classes of antimicrobial to abate the 
threat of AMR. Specifically, they found that most antibiotics are derived from existing antibiotic classes and these 
are only considered a temporary solution to AMR as they will be quickly rendered ineffective by existing resist-
ance mechanisms. Expressly they state that more investment is needed in fundamental drug discovery to discover 
more innovative antimicrobials against priority pathogens including Mycobacterium tuberculosis, Clostridium 
difficile and Staphylococcus aureus2.
One class of antimicrobial that is receiving increased attention is the bacteriocins. These are stable peptides 
naturally produced by many bacteria and have potent activity against other bacteria including antimicrobial 
resistant pathogens3. Bacteriocin production by intestinal strains is considered a desirable probiotic trait that 
could potentially mediate an effect in three different ways; it may allow the producing strain to compete in the 
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crowded gut ecosystem, it could provide protection to the host against pathogens and could potentially signal the 
immune system in a similar fashion to host antimicrobial peptides (AMPs)4–7.
Recently, we described bactofencin A, a small, positively charged bacteriocin produced by the porcine gut 
isolate L. salivarius DPC6502. Structurally, it consists of a positively charged N terminal attached to a C terminal 
loop formed via a disulfide bond between Cys7 and Cys22. Bactofencin A is highly cationic and has been com-
pared to eukaryotic defensins which contain a high Lys/Arg molar ratio considered essential for bactericidal 
activity8,9. Another unusual feature of bactofencin A is that immunity is mediated through a dltB homologue 
proposed to decrease the negative charge of the cell wall thereby reducing attraction between bacteriocin and cell, 
rather than a specific immunity protein. Bactofencin A displays activity against S. aureus and Listeria spp. and has 
been shown to subtly modify gut populations10,11.
The rational design of novel antimicrobials is rapidly evolving via the use of bioengineering to generate novel 
bacteriocin variants with enhanced functionality. This has been realised through the recent generation of both one 
and two peptide bacteriocins with greater activity against food-borne and medically significant Gram-positive 
and Gram-negative pathogens12–17. Indeed, nisin V, a single Met21Val substitution variant of the well charac-
terised commercial bacteriocin nisin A generated in our laboratory, has greater in vivo efficacy against Listeria 
monocytogenes when compared with the native peptide18. In many cases, the identification of enhanced deriva-
tives has been realised following initial studies in which saturation or scanning mutagenesis have been employed 
to reveal key important residues and structures within the peptide12.
The aim of this study was to determine the importance of specific residues and regions within bactofencin A to 
its anti-S. aureus activity. Bactofencin A is a relatively short Class IId peptide in which a disulfide bond naturally 
forms, making it especially amenable to peptide synthesis as a means of carrying out such structure-function 
investigations. Specifically a saturation approach was undertaken as follows; firstly, both cysteines were substi-
tuted with serine and alanine, individually and in tandem, to elucidate their role in peptide structure. Secondly, 
deleted variants were synthesised to assess the function of the positively charged N terminal. Thirdly, alanine was 
substituted for each amino acid (alanine scanning) and finally, a series of D-amino acid variants specific to the 
loop were synthesised to determine if chiral interactions with a receptor were likely to be involved in activity.
Materials and Methods
Peptide synthesis. Bactofencin A and variants were synthesised from the C terminus to the N terminus 
using microwave-assisted solid phase peptide synthesis (MW-SPPS) on a Liberty Blue microwave peptide syn-
thesizer (CEM Corporation. Mathews, North Carolina, USA). Peptides with a C terminal cysteine were synthe-
sized on an H-Cys(Trt)-HMBP pre-loaded resin, bactofencin C22A on an H-Ala-HMBP resin and bactofencin 
C22Cd on HMBP resin where the initial D-Cys was manually added to the resin (PCAS BioMatrix Inc., Quebec, 
Canada). The amino acid attached to the resin and the following two amino acids were deprotected conven-
tionally at 25 °C, 0 W for 900 seconds in 5% piperizine in DMF to limit the formation of an undesirable 51 Da 
modification commonly seen in C terminal cysteine peptides. Following deprotection the exposed amino group 
is coupled conventionally with the carbonyl group of the next amino-protected amino acid at 75 °C, 0 W for 
3600 seconds in the presence of the activator, 0.5 M N,N′-diisopropylcarbodiimide in DMF, and activator base, 
1.1 M hydroxybenzotriazole in DMF. The fourth and subsequent amino acids were added using microwave depro-
tection at 75 °C, 60 W for 600 seconds and microwave coupling at 75 °C, 35 W for 600 seconds. Arginines were 
double coupled at 75 °C, 35 W, 300 seconds and histidine and cysteine coupled at 25 °C, 0 W, 300 seconds and then 
50 °C, 35 W for 900 seconds. Following synthesis, the peptide was cleaved from the resin by adding a cleavage mix 
containing 9.25 ml trifluoroacetic acid (TFA), 250 µl water, 250 µl 2′2-(ethylenedioxy)-diethanethiol and 500 µl 
triisopropylsilane. This mixture was then heated at 37 °C for 1 hour to cleave the peptide from the resin. Resin was 
removed from the cleavage mix using an Accent Cleavage system (CEM, Corporation. Mathews, North Carolina, 
USA) and the TFA evaporated by bubbling with nitrogen. Peptide was precipitated from the remaining solution 
by adding 45 ml of diethyl ether pre-cooled to −20 °C and centrifuging at 1000 g for 3 minutes. The precipitated 
peptide was washed free of scavengers by resuspending in a second aliquot of 45 ml ice cold diethyl ether and the 
centrifugation step repeated.
Purification of synthetic peptides. Crude peptide was purified using Reversed Phase-HPLC on a semi 
preparative Jupiter Proteo (10 × 250 mm, 4 µ, 90 Å) column (Phenomenex, Cheshire, UK) running an 11–45% 
acetonitrile 0.1% TFA gradient over 40 minutes where buffer A is Milli Q water containing 0.1% TFA and buffer B 
is 90% acetonitrile containing 0.1% TFA. Fractions with the desired molecular mass were identified using matrix 
assisted laser deionisation -time of flight-mass spectrometry (MALDI-TOF-MS) on an Axima TOF2 MALDI 
TOF mass spectrometer (Shimadzu Biotech, Manchester, UK) operating in positive ion reflectron mode and 
were pooled and lyophilized on a Genevac HT 4X lyophilizer (Genevac Ltd., Ipswich, UK). Peptides were resus-
pended in 50 mM sodium phosphate buffer pH 6.8 at approximately 1000 µM and kept at room temperature for 
24–48 hours until the disulfide bond between Cys7 and Cys22 fully formed as monitored by MALDI-TOF-MS. 
Peptides were then further purified by a second HPLC run as described above except the gradient used was 
15–30% acetonitrile 0.1% TFA gradient over 30 minutes. Again fractions containing pure bactofencin A were 
identified and lyophilised for specific activity experiments.
Purification of natural bactofencin A. Bactofencin A was purified from MRS culture media as described 
by O’Shea et al.10. Briefly peptide was purified from an overnight culture of L. salivarius grown in 1 litre of MRS 
media using SP sepharose Cation Exchange, C18 Solid Phase Extraction (SPE) and Reversed Phase HPLC.
Specific activity of bactofencin A variants. Peptides were resuspended at 1000 µM in 50 mM sodium 
phosphate buffer pH 6.8 and checked for purity by MALDI-TOF-MS. Peptides were serially diluted 1 in 4 to give 
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a dilution series of 250, 62.50, 15.63, 3.91, 0.98 and 0.24 µM and assayed by the agar well diffusion assay described 
by Ryan et al.19. Briefly, 50 µl aliquots of each peptide concentration were plated on a S. aureus DPC5246 indicator 
plate and the plate incubated at 37 °C. Peptide activity (Minimum Inhibitory Concentration (MIC)) was taken 
as the lowest concentration of peptide to give a zone of inhibition. All assays were performed in triplicate. The 
dilution series values were rounded to the nearest whole number to give 1000, 250, 63, 16, 4, 1 and 0.25 µM and 
data is colour coded for ease of interpretation.
Bactofencin variants synthesised for specific activity studies. Bactofencin A, KRKKHRCRVY 
NNGMPTGMYRWC, is a 22 amino acid bacteriocin with a disulfide bond between Cys7 and Cys22. Bactofencin 
variants are labelled according to the amino acid position number using the one letter code followed by the 
change it undergoes e.g. a lysine at position 1 to alanine change is labelled K1A.
Bactofencin Cys7 and Cys22 were substituted with serine both individually and in tandem to give bactofencin 
C7S, bactofencin C22S and bactofencin C7S-C22S. These amino acids were also substituted with alanine to give 
bactofencin C7A, bactofencin C22A and bactofencin C7A-C22A.
To assess the importance of the positively charged N terminal the following deletion variants were synthesised; 
bactofencin R2-C22, K3-C22, K4-C22, H5-C22, R6-C22 and C7-C22.
Each amino acid in bactofencin A was changed to alanine to give a library of alanine scanning variants, these 
are specifically K1A, R2A, K3A, K4A, H5A, R6A, C7A, R8A, V9A, Y10A, N11A, N12A, G13A, M14A, P15A, 
T16A, G17A, M18A, Y19A, R20A, W21A and C22A. Bactofencin C7A and C22A were also used to assess the role 
of cysteine in activity as described above.
Each amino acid in the loop from Cys7 to Cys22 was substituted for a D-amino acid equivalent to give a series 
of variants namely bactofencin C7Cd, R8Rd, V9Vd, Y10Yd, N11Nd, N12Nd, M14Md, P15Pd, T16Td, M18Md, 
Y19Yd, R20Rd, W21Wd and C22Cd. An all D-amino acid variant for a preliminary MIC50 assay was synthesised 
by Alta Bioscience (Birmingham, UK).
Comparison of bactofencin A and bactofencin R8Q. Bactofencin R8Q and bactofencin R8K were syn-
thesised as described above and their activity compared to bactofencin A against S. aureus DPC5246, Listeria 
innocua DPC3572 and L. monocytogenes ATCC 23074.
Results
Formation of the disulfide bond in synthetic bactofencin A. To investigate how specific residues and 
domains within bactofencin A contribute to its potency against staphylococci, a series of bactofencin variants 
were synthesized, purified and assayed. Natural bactofencin A is encoded on a four gene operon that includes 
an accessory protein that ensures the correct formation of the disulfide bond10. Although synthetic peptides are 
initially synthesized without a disulfide bond, this bond appears to form naturally given that we can detect it by 
MALDI TOF MS. Synthetic bactofencin A (2784 Da) in the reduced form was resuspended in sodium phosphate 
buffer pH 6.8 at 1000 µM, and bond formation (i.e. presence of peptide at 2782 Da) monitored over time by 
MALDI TOF MS analysis (data not shown). For subsequent investigations, synthetic peptides were HPLC puri-
fied, resuspended in sodium phosphate buffer until disulfide bond formation occurred (where appropriate), as 
confirmed by MALDI TOF MS, and then HPLC purified for a second time to obtain pure peptide with an intact 
disulfide bond.
Comparison of natural and synthetic bactofencin A. The yield of natural bactofencin A following 
purification from L. salivarius DPC6502 culture media is generally very low (<0.3 mg/L) making it difficult to 
generate sufficient peptide for structure/function experiments and making genetic approaches to generating 
peptide variants impractical. Bactofencin A, being a small 22 amino acid peptide with a single disulfide, is well 
suited to peptide synthesis and this approach generated milligram quantities of peptide variants for specific activ-
ity studies. Comparison of activity of natural bactofencin A (2782 Da) with synthetic reduced bactofencin A 
(2784 Da) and synthetic oxidised bactofencin A (2782 Da) showed that all peptides were equally active against 
S. aureus DPC5246 (Fig. 1).
Figure 1. Activity (µM) of oxidized synthetic bactofencin A (BFo), reduced bactofencin A (BFr) and natural 
bactofencin A (BFn) against S. aureus DPC5246 (A) and molecular mass of oxidized synthetic bactofencin A 
(Top), reduced bactofencin A (Middle) and natural bactofencin A (Bottom) (B).
www.nature.com/scientificreports/
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The role of cysteines in bactofencin A. To assess the contribution of the cysteines to the activity of 
bactofencin A, Cys7 and Cys22 were replaced with serine. The results (Fig. 2) show that replacing Cys7 with 
serine results in a 63 fold reduction in activity and replacing Cys22 caused an even more detrimental 250 fold 
reduction in activity. Notably, replacing both Cys7 and Cys22 with a serine residue resulted in activity comparable 
to the C7S change alone. Replacing individual cysteine residues with alanine had less of a negative effect than ser-
ine substitution as a C7A change reduces activity 16 fold and C22A is reduced 63 fold. The C7A-C22A variant is, 
like the serine equivalent, comparable with the single C7A variant being 16 fold reduced. Overall, it was apparent 
that substituting Cys22 with either serine or alanine resulted in peptides with lower activity than those generated 
containing Cys7-Cys22 substitutions.
The role of the N terminal positively charged tail. Bactofencin is characterized by a cationic N termi-
nal, KRKKHR, where 5 out of 6 amino acids are positively charged at neutral pH. To determine how this feature 
contributes to the activity of the peptide, a series of deletion variants were synthesized including R2-C22, K3-C22, 
K4-C22, H5-C22, R6-C22 and C7-C22. The specific activity of each peptide against S. aureus was determined and 
reveals that deleting the first two amino acids has no effect on activity. The further exclusion of Lys3 (K4-C22), 
Lys4 (H5-C22) and His5 (R6-C22) resulted in sequential 4 fold reductions in activity resulting in MICs of 4 µM, 
16 µM and 63 µM, respectively. Deleting the entire positively charged N terminal region resulted in a looped pep-
tide for which no activity could be detected (MIC >1000 µM; Fig. 3).
Alanine Scanning. A series of alanine scanning variants, where each individual amino acid was replaced by 
alanine, were synthesized and their activity assessed. The results show that changing individual amino acids to 
alanine within the N terminal region had no effect on activity. This was also the case for the R8A, P15A, M18A, 
Y19A, R20A and W21A containing peptides. As noted previously, the C7A and C22A variants were 16 fold and 63 
fold less active, respectively. Substitutions between V9A and G17A show reduced activity with V9A, Y10A, N12A 
Figure 2. (A) Cys7 and Cys22 were substituted individually and in tandem with serine and alanine to give 
bactofencin variants C7S, C22S, C7S-C22S, C7A, C22A, C7A-C22A. Activity (µM) of bactofencin A compared 
to bactofencin cysteine variants C7S, C22S, C7S-C22S, C7A, C22A and C7A-C22A is presented in (B).
Figure 3. (A) Activity (µM) of bactofencin A and deletion variants, R2-C22, K3-C22, K4-C22, H5-C22, R6-C22 
and C7-C22 against S. aureus DPC5246. (B) Activity (µM) of bactofencin A and deletion variants against  
S. aureus DPC5246. Activity is colour coded with green being most active and red inactive.
www.nature.com/scientificreports/
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and G17A being 4 fold less active and N11A, G13A, M14A and T16A being 16 fold less active (Fig. 4), thereby 
highlighting that this region is highly important for the antimicrobial activity of the peptide.
D-amino acid substitution of the loop. The generation of peptides containing D-amino acids provides 
an insight into the importance of chirality across the whole peptide or within specific regions. As preliminary 
experiments showed that an all D-variant with every amino acid changed was inactive (MIC50 >20 µM; data 
not shown), a series of D-amino acid variants from C7-C22 were synthesized. The D-amino acid substitutions 
(Fig. 5) were all found to be detrimental to activity – even more so than the equivalent alanine substitutions 
(with the exception of C7 and N12 which are equally detrimental at 16 and 4 μM, respectively). In the case of 
C22, the Ala substitution (MIC = 63 µM) is much less active than the C22Cd equivalent (MIC = 4 µM). As for 
Figure 4. (A) Serial dilutions of each alanine variant plated on S. aureus DPC5246 indicator plates and (B) 
shows activity (µM) of bactofencin alanine variants against S. aureus DPC5246. Activity is colour coded with 
green being most active and red least active.
Figure 5. Activity (µM) of bactofencin D-variants C7Cd-C22Cd against S. aureus DPC5246. Activity is colour 
coded with green being most active and red inactive. Amino acids most affected by D-substitution are circled in 
(A) and activities presented in (B).
www.nature.com/scientificreports/
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the alanine-containing variants, the substitution of amino acids within the R8-Y19 region of the peptide has a 
particularly deleterious impact as bactofencin R8Rd, V9Vd, M14Md and Y19Yd are 63 fold less active than wild 
type and Y10Yd, N11Nd, P15Pd and T16Td are inactive at 1000 µM, the highest concentration tested.
Comparison of bactofencin A with bactofencin R8Q (plantaricin ST31), a potential natural variant. 
Todorov et al. (1999) previously described plantaricin ST31, a bacteriocin with an amino acid sequence deter-
mined to be KRKKHRXQVYNNGMPTGMYR, produced by a sourdough isolate Lactobacillus plantarum ST31, 
with a reported mass of 2755 + /− 0.3 Da20. Substitution of Cys for X results in a peptide with a mass of 2468 Da. 
However if tryptophan and cysteine, the C terminal amino acids of bactofencin A are included, a mass of 2757 Da 
is obtained and subsequent oxidation of cysteines gives the published mass, 2755 Da. This suggests that planta-
ricin ST31 is likely to be a variant of bactofencin A with an arginine to glutamine change at position 8. Although 
plantaricin ST31 was reported as inactive against Listeria spp., bactofencin A is active against Listeria at high 
concentrations. For this reason, it was decided to directly compare the activity of bactofencin R8Q (i.e. plantaricin 
ST31) and bactofencin A against S. aureus DPC5246, L. innocua DPC3572 and L. monocytogenes ATCC 23074. 
Although bactofencin A and bactofencin R8Q (plantaricin ST31) were equally active at 1 µM against S. aureus 
DPC5246, it was established that bactofencin A is indeed more active (63 µM) than bactofencin R8Q (plantaricin 
ST31; 250 µM) against L. innocua DPC3572 and L. monocytogenes ATCC 23074. The reduced activity of R8Q was 
not evident after a substitution that retained the charge at position 8, i.e. R8K (Fig. 6).
Discussion
There is an urgent need for new antimicrobials to combat infection and bactofencin is a clear candidate. Although 
it is produced in small amounts by the producing strain, the lack of post translational modifications makes it very 
accessible to synthesis strategies. With this in mind, we generated a bank of synthetic variants which included 
a number of amino acid substitution and deletion variants. Preliminary experiments showed that the disulfide 
bond forms naturally over time and that synthetic bactofencin with an intact disulfide is as active as the native 
peptide making this a valid approach (Fig. 1). The synthetic peptide with reduced cysteines was also found to be 
as active as natural bactofencin suggesting that the disulfide bond is not essential for full activity (Fig. 1).
Substituting either cysteine with serine resulted in peptide variants with lower activity than alanine equiva-
lents proving that serine is not a good substitute for cysteine in bactofencin A (Fig. 2). Cysteines and serines differ 
in both chemical and physical properties as cysteines are often found in the interior of a molecule especially when 
involved in disulfide bond formation while comparatively hydrophilic serines are typically exposed21,22. Alanine, 
however, is hydrophobic so it is possible that hydrophobic interactions between C7A and C22A are stronger than 
serine equivalents and so can better maintain structural conformation. This was seen when Cys9 and Cys14 resi-
dues of the Class IIa leucocin A were replaced with hydrophobic equivalents23. It appears that single C22 changes 
to either serine or alanine have a greater negative impact on activity than the corresponding C7 and C7-C22 
changes. The possibility here is that substituting C22 alone with serine or alanine may introduce steric hindrance, 
thus preventing any semblance of loop conformation resulting in a less active peptide. Disulfides have a very dis-
tinct role in stabilizing protein structure22 and the results of this study suggest that the presence of both cysteines 
play a key role in maintaining peptide structure and are required for full activity of bactofencin A.
Sequential deletion of the positively charged N terminal from Lys3 to Arg6 resulted in a series of variants 
with decreasing activity against S. aureus DPC5246, while removal of the entire N terminal region prior to the 
loop resulted in an inactive peptide (Fig. 3). Interestingly, the C7-C22 variant contained an intact disulfide bond 
as determined by MALDI TOF MS. The N terminal, KRKKHR, with a charge of + 5 at neutral pH is unique 
among known Class II bacteriocin sequences and invites conjecture as to its function. Lysine and arginine play 
an important role in the interaction with negatively charged phospholipid membranes. Indeed, arginine is more 
effective than lysine in this regard as it forms more extensive H bonding, thereby stabilizing arginine-phosphate 
clusters enabling enhanced interfacial binding leading to membrane disruptions24. In addition, a high positive 
charge allows bacteriocins and AMPs to insert further into membranes25. It may be that KRKKHR plays a role in 
binding to anionic lipids in cell membranes and that a charge of at least +3 at the N terminus is required for full 
activity, given that variants with a lower charge were significantly less active (Fig. 3). The highly positive charge 
of bactofencin A may also have played a role in the evolution of the unique bacteriocin immunity associated 
with the producer, L. salivarius DPC6502. In this respect, immunity is mediated through a homologue of DltB a 
protein which results in the reduction in the charge of teichoic acids in the cell wall. Thus the mechanism medi-
ating immunity could be through reducing the affinity of the positively charged bactofencin A to the producer 
surface10.
Figure 6. Activity (µM) of bactofencin A (A) bactofencin R8Q (plantaricin ST 1) and bactofencin R8K against 
S. aureus DPC5246 (A) L. innocua DPC3572 (B) and L. monocytogenes ATCC 23074 (C).
www.nature.com/scientificreports/
7SCIenTIFIC REPORTS |  (2018) 8:11833  | DOI:10.1038/s41598-018-30271-6
Alanine scanning mutagenesis approaches have been successfully used to study the lantibiotic, lacticin 314726 
and the Class IIa bacteriocin, durancin GL27. In bactofencin A, replacing the amino acids of the N terminal with 
alanine did not lead to a reduction of activity when compared to the native peptide. This correlates with the results 
from the deletion experiment as it is expected that the loss of a single positive charge would not adversely affect 
activity. Changing Cys7 to alanine does have an effect but this is expected due to possible structural changes in 
the peptide as speculated earlier. Changes to Arg8 and the C terminal side of the loop were also well tolerated as 
R8A, P15A, M18A, Y19A, R20A and W21A are as active as bactofencin A. However, when residues between Val9 
and Gly17 are changed to alanine activity is significantly reduced, suggesting that this part of the loop makes an 
important contribution to activity (Fig. 4).
D-amino acid substitutions were used to investigate the importance of stereochemistry for target interaction 
as introduction of D-amino acids typically disrupts the helicity of AMPs28. The retention of significant levels of 
activity in an all D variant of AMPs suggests the natural peptide functions by interacting with the lipid mem-
brane, rather than a specific receptor, whereas a significant reduction in activity among such variants suggests 
that a stereospecific target, such as a membrane receptor, is involved in activity29. The latter proved to be the case 
for bactofencin A. Substituting the amino acids of the loop for D equivalents was detrimental to activity in every 
case but most particularly in peptides with substitutions between Arg8 and Tyr19. Indeed, Y10Yd, N11Nd, P15Pd 
and T16Td were totally inactive at 1000 µM further suggesting a chiral interaction between bactofencin A and 
a specific receptor or that the introduction of a D residue disrupted structural conformation within this region. 
The inactivity of the P15Pd peptide is particularly notable and is in stark contrast to the activity observed with 
the P15A variant, suggesting that kinking the molecule in the opposite direction leads to detrimental structural 
changes.
Taken together, the results from the N-Terminal deletion, alanine scanning and D amino acid variant studies 
make it tempting to suggest that bactofencin A interacts with the cell membrane through initial electrostatic 
interaction with the N terminal and then disrupts the cell through binding with a putative receptor to amino acids 
in the interior of the loop.
The existence of an apparent natural variant of bactofencin A is interesting and provides an opportunity to 
compare the activities of the two peptides, especially in light of the absence of activity in cell free supernatants 
of plantaricin ST31-producing L plantarum ST31 against L. innocua and L. monocytogenes20. This natural sub-
stitution did indeed result in reduced activity against Listeria as evidenced by our studies with bactofencin R8Q 
(plantaricin ST31). Substituting glutamine for lysine, the other positively charged amino acid restored activity 
suggesting that a positive charge is necessary in this position for activity against Listeria.
None of the bactofencin A variants investigated in this study resulted in enhanced anti-staphylococcal activity 
with respect to the native bactofencin suggesting that wild type bactofencin A has close to maximal antimicrobial 
activity. However, the reduction in activity against Listeria spp. due to an R8Q change and its restoration with an 
R8K change suggests that there is potential to change the spectrum of activity of bacteriocins. Ultimately, it will 
now be possible to build on this blueprint to further investigate the fundamental biology underlying the activity 
of bactofencin and, in turn, enhance the spectrum and activity of this cationic bacteriocin.
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